|
|
|
Volumn 5, Issue 5, 2003, Pages 541-546
|
|
Technology evaluation: ABX-EGF, Abgenix/Amgen
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
CYTOTOXIC AGENT;
DOCETAXEL;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;
FLUOROURACIL;
FOLINIC ACID;
GEFITINIB;
IRINOTECAN;
MONOCLONAL ANTIBODY;
PACLITAXEL;
PANITUMUMAB;
ASTHENIA;
BACKACHE;
CANCER IMMUNOTHERAPY;
CLINICAL TRIAL;
COLORECTAL CANCER;
DIARRHEA;
DRUG BLOOD LEVEL;
DRUG HYPERSENSITIVITY;
DRUG INDICATION;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG POTENTIATION;
DRUG SYNTHESIS;
HUMAN;
KIDNEY CANCER;
LUNG NON SMALL CELL CANCER;
NONHUMAN;
PROSTATE CANCER;
RASH;
REVIEW;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
HUMANS;
MICE;
MICE, TRANSGENIC;
NEOPLASMS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 0142154205
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (12)
|
|
References (0)
|
